文献速递心胸血管麻醉术前评估与围术期医学

氨基酸输注对合并慢性肾脏病心脏手术患者的肾脏保护:PROTECTION试验二次分析

Amino Acid Infusion for Kidney Protection in Cardiac Surgery Patients with Chronic Kidney Disease: A Secondary Analysis of the PROTECTION Trial.
PubMed 文献 · Anesthesiology · 2024-12-19

该研究为PROTECTION试验的二次分析,纳入合并慢性肾脏病(估算肾小球滤过率<60 ml·min⁻¹·1.73 m⁻²)的心脏手术患者812例,比较静脉氨基酸与安慰剂对急性肾损伤的影响。结果显示氨基酸显著降低急性肾损伤发生率(43.1% vs 50.3%;RR 0.86;95%CI 0.74–0.99;P=0.041;NNT=14),并减少重度(3期)急性肾损伤(2.7% vs 5.6%;RR 0.48;95%CI 0.24–0.98;P=0.038)。

要点

  • 合并慢性肾脏病心脏手术患者中,氨基酸输注降低急性肾损伤发生率,NNT=14。
  • 氨基酸输注使重度(3期)急性肾损伤相对风险降低超过50%。
  • 不同估算肾小球滤过率亚组(30–59)间氨基酸效应相似(交互P=0.50)。

核心结论

  • 静脉氨基酸输注可保护接受体外循环的慢性肾脏病患者免于发生急性肾损伤。
  • 在急性肾损伤发生率超过45%的队列中,绝对风险降低7%,需治疗人数为14。
  • 氨基酸输注使重度急性肾损伤的相对风险降低超过50%。

研究设计与样本

  • PROTECTION试验的二次分析,慢性肾脏病定义为估算肾小球滤过率<60 ml·min⁻¹·1.73 m⁻²。
  • 慢性肾脏病患者812例,估算肾小球滤过率≥60 ml·min⁻¹·1.73 m⁻²者作为对照。
  • 主要结局为急性肾损伤发生,次要结局包括急性肾损伤严重程度、肾脏替代治疗需求与时长及全因死亡率。

主要发现

  • 慢性肾脏病患者中,氨基酸组急性肾损伤发生率为43.1%,安慰剂组为50.3%(RR 0.86;95%CI 0.74–0.99;P=0.041;NNT=14)。
  • 估算肾小球滤过率从基线至术后第3天的中位百分比增幅,氨基酸组为12.7%,安慰剂组为6.5%(P=0.002)。
  • 估算肾小球滤过率30–39、40–49、50–59 ml·min⁻¹·1.73 m⁻²亚组中氨基酸效应相似(交互P=0.50)。
  • 氨基酸输注降低重度(3期)急性肾损伤发生率(2.7% vs 5.6%;RR 0.48;95%CI 0.24–0.98;P=0.038)。

临床怎么用

  • 对接受体外循环且合并慢性肾脏病(估算肾小球滤过率<60 ml·min⁻¹·1.73 m⁻²)的心脏手术患者,可考虑静脉氨基酸输注以降低急性肾损伤风险。
  • 该人群中氨基酸输注的获益表现为急性肾损伤绝对风险降低7%、NNT=14,以及重度急性肾损伤相对风险降低超过50%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the PROTECTION trial (Intravenous Amino Acid Therapy for Kidney Protection in Cardiac Surgery), intravenous amino acids decreased the occurrence of acute kidney injury in cardiac surgery patients with cardiopulmonary bypass. Recruitment of renal functional reserve may be responsible for such protection. However, patients with chronic kidney disease have diminished renal functional reserve, and amino acids may be less protective in such patients. Thus, a separate investigation of such patients is warranted. METHODS: For this study chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 ml · min -1 · 1.73 m -2 , and patients with estimated glomerular filtration rates greater than or equal to 60 ml · min -1 · 1.73 m -2 served as controls. The primary outcome was the occurrence of acute kidney injury. Secondary outcomes included severity of acute kidney injury, need for and duration of renal replacement therapy, and all-cause mortality. RESULTS: Among chronic kidney disease patients (n = 812), compared with placebo, amino acids significantly decreased the rate of acute kidney injury (43.1% vs 50.3%; relative risk, 0.86; 95% CI, 0.74 to 0.99; P = 0.041; number needed to treat = 14) with a median percentage increase in estimated glomerular filtration rate from baseline to postoperative day 3 of 12.7% versus 6.5% ( P = 0.002). In estimated glomerular filtration rate-based chronic kidney disease subgroups (30 to 39, 40 to 49, and 50 to 59 ml · min -1 · 1.73 m -2 ), the amino acid effect was similar (interaction P = 0.50). Finally, amino acid infusion decreased the occurrence of severe (stage 3) acute kidney injury (2.7% vs . 5.6%; relative risk 0.48; 95% CI, 0.24 to 0.98; P = 0.038). CONCLUSIONS: Amino acid infusion protected chronic kidney disease patients undergoing cardiopulmonary bypass from developing acute kidney injury, with an absolute risk reduction of 7% and a number needed to treat of 14 in a cohort with a greater than 45% rate of acute kidney injury. Moreover, it delivered a greater than 50% relative risk reduction in severe acute kidney injury.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Baiardo Redaelli M, Monaco F, Bradic N, et al. Amino Acid Infusion for Kidney Protection in Cardiac Surgery Patients with Chronic Kidney Disease: A Secondary Analysis of the PROTECTION Trial. Anesthesiology. 2024. PMID: 39705670. doi:10.1097/ALN.0000000000005336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。